Skip to main content

Pump funding - 2008

Not written in ages as I have had so many other things to do - kids, decorating, work etc. I still don't have a great deal of time, but felt industrious this evening whilst watching England fail at cricket, and wrote the following email to an American asking about the situation for UK diabetics:

"Not sure whether you got an answer to the pump question about UK. I think I have a fairly balanced view of it (not common here):

In the UK, we pay taxes which cover most of our medical needs (socialised medicine). Our companies often pay for private medical insurance, but these do not cover chronic conditions like diabetes. As there are limited funds, everyone generally gets the same treatment (in theory) and an organisation called NICE (National Institute for Clinical Excellence) decided what is the best treatment for each condition based on cost and clinical outcome. They have decided (this is a summary) based on the clinical evidence that a) Type 2 diabetics are never eligible for pumps, b) Type 1 diabetics are only eligible if they have severe unforseen hypos or very high a1c's that have not been controlled by all efforts a using mdi.

They (NICE) are currently reviewing the scientific evidence, but as it stands pumps are not widely available and therefore clinical expertise is not great in this area.

It is possible to self-fund a pump, but you also have to fund the clinical assistance (physician consultations) so it is prohibitively expensive. Alternatively health authorities (governance of regional health policy) can decide how they use their finite funds. Some have decided not to follow NICE guidelines, so pumps are available. I expect these policies to change in the nea future but further scientific evidence for the success of pumps needs to be proved and the price of them needs to come down.

Finally, to complete the picture, prescriptions (notes written by doctors (physicians) for medications are charged at £6, $12 a time, but diabetics that are on insulin have free prescriptions for any medication, whether it be related to diabetes or not. Diabetes is one of the very few ailments that falls under this exemption.

Hope you haven't been too bored with this description. Maybe I'll save it to try and help some one else to understand the situation. It is not as bad a situation as some people make it. Just talk to an American diabetic without adequate medical insurance to find out the shortfalls of that system!"

Maybe it is of interest to someone reading this blog....

Comments

Popular posts from this blog

Abbott dX 2022 Barcelona - "Make it Count"

For the past four years I've been invited by Abbott to a conference bringing together people with diabetes from across Europe to discuss various topics.  The first year I was meant to attend, it was my 'man v horse' year (the horse won!), so was unable to attend and then the pandemic hit so two further dX's were held virtually.  I was fortunate to be asked to present at last year's session.  This year's event was back in-person and held in Barcelona, coinciding with the latter part of the ATTD conference.   At this point, I must make it very clear - Abbott invited me to the 2022 European Diabetes Exchange forum (dX), that took place in Barcelona.  I attended this two-day event to connect and interact with inspirational and influential people in the diabetes community.  Abbott paid for my ticket and accommodation. #InvitedbyAbbott.  This is formal and it needs to be - I have not been required to do anything by Abbott as a result of my attendance and I hope that m

The CCG Project!

In order to find out the situation around the country for Libre prescribing now that the national policy has been published, I have made the decision to contact many of them to find out their plans.  I have arbitrarily chosen to contact all English CCGs that in December 2018 prescribed Libre via Primary Care to less than 5% of their population (and one specific request from a group member).  I had hoped this would be a small list, but there are 135 CCGs on the list.  I may have bitten off more than I can chew, but I'm committed to doing this and feeding back.  It worked before and hopefully this level of scrutiny will bring similar results. Below is a screenshot of the base document I am sending to each of the CCGs - it has some fields that are merge fields, so don't worry about the brackets and codes in the document (I found a typo, which has now been corrected too) .  The major piece of work with respect to this is finding the right person to contact.  However, I have s

July Update - CCGs Under Pressure!

The heat is unbearable in some parts, not only in the environment, but also hopefully the heat directed at the decision-makers in 'non-compliant' CCGs who are either refusing to accept that Libre is a revolutionary tool for many T1s or have agreed to fund, but then set crippling criteria. Latest Prescribing Data Progress in prescribing continues, with stabilisation in Scotland and a continuation of the steady rise in the other three countries of the UK.  The Wales May data should be out this week. As mentioned last month, the situation in Scotland is particularly promising and the excellent Edinburgh Centre for Endocrinology and the Scottish Health Technologies Group have published documents that should significantly help the Libre case.  These documents are based on the first six months of prescribing Libre. Healthcare Improvement Scotland Statement Flash Glucose Monitoring is associated with improved glycaemic control and quality of life in people with type 1 d